1. Volume 14, Issue 1, Pages 60-66 (January 2012)
Predictors of response to radio-embolization (TheraSphere®) treatment of neuroendocrine liver metastasis 
Mohammed Shaheen, Mazen Hassanain, Murad Aljiffry, Tatiana Cabrera, Prosanto Chaudhury, Eve Simoneau, Nuttawut Kongkaewpaisarn, Ayat Salman, Juan Rivera, Mohammad Jamal, Robert Lisbona, Azzam Khankan, David Valenti, Peter Metrakos 
HPB 
Volume 14, Issue 1, Pages (January 2012)
DOI: /j x
Copyright © 2012 International Hepato-Pancreato-Biliary Association Terms and Conditions

2. Figure 1
Therasphere therapy after surgical intervention. (a) An abdominal computed tomography (CT) scan showing a previously-treated neuroendocrine tumour (NET) metastatic lesion with radiofrequency ablation (RFA) in segment VII (white arrow) with no enhancement. However, multiple enhancing metastatic nodules (black arrow) are present adjacent to the ablated segment. (b) CT scan images of the same patient 3months after 90Y therapy of the right lobe of the liver showing a complete response. The vascular enhancement has virtually disappeared, but the lesions themselves are persistent
HPB  , 60-66DOI: ( /j x)
Copyright © 2012 International Hepato-Pancreato-Biliary Association Terms and Conditions

3. Figure 2 Overall survival
HPB  , 60-66DOI: ( /j x)
Copyright © 2012 International Hepato-Pancreato-Biliary Association Terms and Conditions